Inquiry Basket
Loading ......
The Newcastle disease virus (NDV), scientifically designated as the Avian orthoavulavirus 1, occupies a highly unique and paradoxical position in modern biology and medicine. To the global agricultural sector, NDV represents an enduring and devastating pathogen capable of wiping out entire poultry flocks, triggering severe economic crises, and disrupting international trade. Conversely, to the biomedical and oncology communities, NDV is heralded as a highly promising biological tool, serving as a potent oncolytic agent and a versatile vaccine vector. Over the past decade, the explosion of genomic sequencing and the refinement of reverse genetics have propelled NDV research to the forefront of translational medicine and molecular epidemiology.
The architectural and genomic structure of NDV is fundamental to understanding both its pathogenic mechanisms in birds and its therapeutic utility in humans. NDV is an enveloped virus belonging to the family Paramyxoviridae. It possesses a non-segmented, negative-sense, single-stranded RNA genome that typically consists of exactly 15,186 nucleotides. This compact genome encodes six major structural proteins: the nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN), and the large polymerase protein (L). The viral envelope is heavily studded with the F and HN glycoproteins, which operate as a coordinated molecular machine to facilitate cellular infection. The HN protein is responsible for the initial attachment of the virion to sialic acid-containing receptors on the host cell surface, while simultaneously preventing viral self-aggregation through its neuraminidase activity. Following attachment, the F protein undergoes a dramatic conformational change that mediates the fusion of the viral envelope with the host cell membrane, allowing the viral ribonucleoprotein complex to enter the cytoplasm.
Figure 1. Schematic representation of the Newcastle disease virus structure
(Source: Berihulay H, et al. 2025)
The primary determinant of NDV virulence is deeply encoded within the structure of the F protein, specifically at its cleavage site. The F protein is synthesized as an inactive precursor (F0) that must be cleaved into two biologically active subunits (F1 and F2) by host cellular proteases. In avirulent (lentogenic) strains, this cleavage site consists of monobasic amino acids that can only be cleaved by trypsin-like proteases found strictly in the respiratory and intestinal tracts, restricting the infection to a localized and mild disease. In stark contrast, highly virulent (velogenic) strains possess a multi-basic amino acid motif at the cleavage site. This multi-basic site is easily recognized and cleaved by furin-like intracellular proteases, which are ubiquitously distributed across almost all host tissues. This fundamental structural difference allows velogenic NDV to replicate systemically, causing massive viremia, devastating neurological and hemorrhagic tissue damage, and overwhelming mortality in avian hosts.
From an epidemiological perspective, the global landscape of Newcastle disease is constantly evolving, driven by high viral mutation rates and complex global trade networks. NDV isolates are broadly divided into two major classes (Class I and Class II). While Class I viruses are generally avirulent and circulate predominantly in wild waterfowl, Class II encompasses the vast majority of virulent strains responsible for global panzootics. Within Class II, viruses are further categorized into numerous distinct genotypes. Currently, contemporary scientific discourse and international agricultural surveillance are heavily focused on Genotype VII. This specific genotype has become the dominant genetic lineage across Asia, Africa, and the Middle East over the last decade, driving a continuous wave of severe outbreaks. The rise of Genotype VII has highlighted a critical vulnerability in global poultry management: while traditional, decades-old lentogenic vaccine strains (such as LaSota) prevent clinical disease and mortality, they do not completely halt viral shedding when challenged with phylogenetically distant Genotype VII field strains. Consequently, the virus continues to circulate and evolve silently within vaccinated flocks. This dynamic has sparked a massive push in veterinary virology to develop genotype-matched vaccines that can induce sterile immunity and effectively break the chain of transmission in highly endemic regions.
Beyond its role as an agricultural pathogen, NDV has captured the intense focus of the global biomedical community due to its extraordinary potential as an oncolytic virus. The premise of oncolytic virotherapy lies in utilizing replication-competent viruses to selectively infect, replicate within, and destroy malignant cancer cells while sparing normal, healthy tissues. NDV is uniquely suited for this task due to its natural biological properties. Because NDV is an avian virus, humans generally lack pre-existing neutralizing antibodies against it, allowing the virus to be administered systemically without being immediately neutralized by the human immune system. More importantly, NDV replication is highly sensitive to the antiviral effects of interferon. In healthy human cells, a robust interferon response rapidly suppresses NDV replication. However, the vast majority of human tumor cells have heavily mutated or defective interferon signaling pathways, a trade-off they make to evade the host's immune surveillance and achieve unchecked cellular proliferation. This exact cellular defect renders the tumor cells exquisitely permissive to massive NDV replication and subsequent viral-mediated lysis.
Figure 2. Schematic illustration of mechanisms of anti-tumor activity of NDV
(Source: Schirrmacher V. 2022)
The destruction of tumor cells by NDV is not merely a physical process; it is a profound immunological event. Modern oncology heavily emphasizes the concept of "immunogenic cell death," and NDV is a master inducer of this phenomenon. When NDV lyses a cancer cell, it causes the release of copious amounts of tumor-associated antigens, danger-associated molecular patterns (DAMPs), and pro-inflammatory cytokines into the surrounding tumor microenvironment. This massive molecular alarm effectively breaks the immune tolerance that the tumor had carefully constructed, transforming an immunologically "cold" tumor into a "hot" one. This influx recruits and activates dendritic cells, macrophages, and cytotoxic T-lymphocytes, essentially retraining the patient's own immune system to recognize and attack distant metastatic lesions that were not even directly infected by the virus. Currently, the most exciting and highly searched frontier in this space is the combination of oncolytic NDV with immune checkpoint blockade therapy. By utilizing NDV to inflame the tumor microenvironment, researchers have demonstrated that tumors previously resistant to checkpoint inhibitors become highly susceptible, leading to synergistic therapeutic outcomes that are currently being evaluated in multiple human clinical trials.
Parallel to its oncological applications, NDV has emerged as a premier platform for recombinant vaccine vectors, largely due to the maturation of reverse genetics technology. Reverse genetics allows scientists to essentially write and edit the viral genome from scratch using cloned complementary DNA (cDNA). Because the NDV genome is highly stable and does not integrate into host cell DNA, it provides a remarkably safe and reliable scaffold for expressing foreign antigens. Furthermore, the modular nature of the NDV genome allows for the insertion of large genetic cassettes between its endogenous genes.
In veterinary medicine, reverse genetics has been utilized to create powerful bivalent vaccines. For example, researchers have successfully engineered avirulent NDV strains to express the hemagglutinin (HA) protein of highly pathogenic avian influenza (HPAI). A single inoculation of this recombinant virus provides poultry with robust, simultaneous protection against both Newcastle disease and avian influenza, drastically reducing the logistical burden on farmers. In human medicine, NDV vectors have gained immense traction, particularly highlighted during recent global health emergencies. Because NDV shares no significant homology with human pathogens, it serves as an excellent vector to deliver antigens for human respiratory viruses without the complication of vector immunity. Moreover, NDV replicates to extraordinarily high titers in embryonated chicken eggs—the exact same highly scalable, low-cost manufacturing infrastructure used globally for the seasonal flu vaccine. This makes NDV-vectored human vaccines uniquely suited for rapid, cost-effective global deployment during pandemic scenarios.
References
| Target | Cat. No. | Product Name | Size | Species | Application | |
| NDV | DElABL41 | Chicken Newcastle Disease Virus antibody (NDV Ab) ELISA Kit | 96T | Quantitative | Inquiry | |
| DEIABL41 | Chicken Newcastle Disease Virus antibody (NDV Ab) ELISA Kit | 96T | Chick | Quantitative | Inquiry | |
| DEIA-VT005 | Chicken newcastle disease virus(NDV) antibody ELISA Kit | 96T | Chicken | Qualitative | Inquiry | |
| DEIA1064 | NDV antibody ELISA Kit | 96T | Qualitative | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| NDV | DAG-WT1120 | Recombinant Newcastle Disease Virus F Protein | Mammalian cells | His | Immunoassays | Inquiry |
| DAGF-103 | Recombinant Newcastle Disease Virus Nucleoprotein (aa1-489) [His] | E. coli | His | Inquiry | ||
| DAGF-104 | Native Newcastle disease virus Antigen | Chicken | Unconjugated | Inquiry |
Loading ......
